Related Experiment Videos

[Model of a miniature pig catheterized for pharmacokinetic and pharmacodynamic studies of anti-infective agents]

J Salmon1, D Levêque, J D Peter

  • 1Institut de Bactériologie - Laboratoire de Pharmacocinétique, Strasbourg, France.

Insights

This study introduces a chronic catheterized micropig model for long-term pharmacokinetic investigations of anti-infective agents. The model allows for extended drug studies in a relevant animal model, overcoming previous limitations.

Area of Science:

  • Veterinary Medicine
  • Pharmacology
  • Biomedical Research

Background:

  • Miniature pigs share physiological and anatomical similarities with humans, making them valuable research models.
  • Despite their suitability, miniature pigs are underutilized in experimental pharmacokinetic studies.
  • A need exists for reliable, long-term animal models for drug investigation.

Purpose of the Study:

  • To develop and validate a chronic catheterized micropig model for long-term pharmacokinetic and pharmacodynamic investigations.
  • To assess the feasibility and limitations of using catheterized micropigs for anti-infective agent studies.
  • To establish a reproducible method for chronic drug administration and blood sampling in micropigs.

Main Methods:

  • Yucatan adult female micropigs (20-40kg) were utilized in a chronic model.
  • A jugular vein catheter was surgically implanted for long-term access.
  • Anti-infective agents were administered via ear vein, with blood samples collected through the jugular catheter.

Main Results:

  • The chronic catheterized micropig model demonstrated a mean viability of 13 weeks (SD: 10 weeks).
  • Thrombosis was identified as the primary factor limiting the model's duration.
  • The model successfully facilitated pharmacokinetic studies of anti-infective agents.

Conclusions:

  • The chronic catheterized micropig model is suitable for extended pharmacokinetic and pharmacodynamic investigations of anti-infective agents.
  • This model offers a valuable tool for preclinical drug development, particularly for anti-infectives.
  • Further refinement could address thrombosis to enhance model longevity.

Related Concept Videos